Merck moves to secure access for new HIV prevention pill as generics target $5 annual cost

Merck announced a new HIV prevention pill that has generated optimism among public health officials. The company is taking steps to ensure the drug reaches patients worldwide. Merck announced a new HIV prevention pill that has generated optimism among public health

officials. The company is taking steps to ensure the drug reaches patients worldwide. Generic manufacturers in Africa and India have agreed to produce the pill. These generics could be priced as low as $5 per person each year. The low price aims to make the

prevention method affordable for low‑income populations. However, distribution plans for much of Latin America are still uncertain. Unclear access in the region could limit the pill’s impact on HIV transmission rates. Merck and health agencies will monitor rollout

and address supply challenges as they arise.